3-[5-(4-chloro-phenyl)-3-methyl-3H-[1,3,4]thiadiazol-2-ylideneamino]-benzoic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-[5-(4-chloro-phenyl)-3-methyl-3H-[1,3,4]thiadiazol-2-ylideneamino]-benzoic acid
• 化学式: C₁₆H₁₂ClN₃O₂S
• 分子量: 345.809
• InChiKey: ARXGWWJAFSVHBR-VLGSPTGOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.73
• 重原子数：
  23.0
• 可旋转键数：
  3.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  67.48
• 氢给体数：
  1.0
• 氢受体数：
  5.0

反应信息

• 作为产物：
  描述：

  间氨基苯甲酸 、 5-(4-chlorophenyl)-3-methyl-2-(methylthio)-1,3,4-thiadiazolium perchlorate 在 三乙胺 作用下， 以 乙醇 为溶剂， 生成 3-[5-(4-chloro-phenyl)-3-methyl-3H-[1,3,4]thiadiazol-2-ylideneamino]-benzoic acid
  参考文献：
  名称：

  噻二唑类作为有效和选择性PDE7抑制剂的新型结构类别的发现。第1部分：设计，合成和构效关系研究。

  摘要：

  讨论了一系列结构新颖的PDE7小分子抑制剂的合成和SAR研究。该系列中最好的化合物显示出较低的纳摩尔抑制活性，并且相对于PDE4具有选择性。

  DOI：

  10.1016/j.bmcl.2004.07.008

文献信息

• New thiadiazoles and their use as phosphodiesterase-7 inhibitors
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP1193261A1

  公开（公告）日：2002-04-03

  The invention provides 1,3,4-thiadiazoles having the following formula (I): in which, R1 is alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, aryl, heteroaryl or a polycyclic group, optionally substituted, R2 is alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl or aryl optionally substituted, R3 is X2-R'3, in which X2 is a binding group and R'3 is cycloalkyl, heterocycloalkyl, cycloalkenyl, aryl, heteroaryl, or a polycyclic group; optionally substituted, or their pharmaceutically acceptable derivatives, the process for their preparation and their use for the manufacture of a medicament for the treatment of disorders for which a treatment by a PDE7 inhibitor is relevant.

  该发明提供具有以下式（I）的1,3,4-噻二唑： 其中， R1是烷基，烯基，炔基，环烷基，杂环烷基，环烯基，芳基，杂芳基或多环基团，可选择性取代， R2是烷基，烯基，炔基，环烷基，杂环烷基，环烯基或芳基，可选择性取代， R3是X2-R'3，其中X2是一个结合基团，R'3是环烷基，杂环烷基，环烯基，芳基，杂芳基或多环基团；可选择性取代，或它们的药学上可接受的衍生物， 它们的制备方法及其用于制备治疗PDE7抑制剂相关疾病的药物的用途。
• Thiadiazoles and oxadiazoles and their use as phosphodiesterase-7 inhibitors
  申请人：——

  公开号：US20030045557A1

  公开（公告）日：2003-03-06

  The invention provides 1,3,4-thiadiazoles and 1,3,4-oxadiazoles having the following Formula I: 1 in which, Y is S or O, R 1 is alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, aryl, heteroaryl or a polycyclic group, optionally substituted, R 2 is alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl or aryl optionally substituted, R 3 is X 2 —R′ 3 , in which X 2 is a binding group and R′ 3 is cycloalkyl, heterocycloalkyl, cycloalkenyl, aryl, heteroaryl, or a polycyclic group; optionally substituted, or their pharmaceutically acceptable derivatives, a compound of Formula I, for their preparation, and processes for pharmaceutical compositions containing methods of using the compounds for the treatment of disorders for which a treatment by a PDE7 inhibitor is relevant.

  该发明提供具有以下式I的1,3,4-噻二唑和1,3,4-氧二唑：其中，Y为S或O，R1为烷基、烯烃基、炔烃基、环烷基、杂环烷基、环烯基、芳基、杂芳基或多环基，可选地取代，R2为烷基、烯烃基、炔烃基、环烷基、杂环烷基、环烯基或芳基，可选地取代，R3为X2—R′3，其中X2为结合基团，R′3为环烷基、杂环烷基、环烯基、芳基、杂芳基或多环基；可选地取代，或其药学上可接受的衍生物，式I的化合物，用于它们的制备，以及含有该化合物的制药组合物的处理方法，用于治疗需要通过PDE7抑制剂进行治疗的疾病。
• [EN] NEW THIADIAZOLES AND OXADIAZOLES AND THEIR USE AS PHOSPHODIESTERASE-7 INHIBITORS<br/>[FR] NOUVEAUX THIADIAZOLES ET OXADIAZOLES ET UTILISATION DE CEUX-CI COMME INHIBITEURS DE LA PHOSPHODIESTERASE DE TYPE 7
  申请人：WARNER LAMBERT CO

  公开号：WO2002028847A1

  公开（公告）日：2002-04-11

  The invention provides 1,3,4-thiadiazoles and 1,3,4-oxadiazoles having the following formula (I):in which, Y is S or O,R1 is alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, aryl, heteroaryl or a polycyclic group, optionally substituted,R2 is alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl or aryl optionally substituted,R3 is X2-R'3, in which X2 is a binding group and R'3 is cycloalkyl, heterocycloalkyl, cycloalkenyl, aryl, heteroaryl, or a polycyclic group; optionally substituted,or their pharmaceutically acceptable derivatives,the process for their preparation and their use for the manufacture of a medicament for the treatment of disorders for which a treatment by a PDE7 inhibitor is relevant.

  本发明提供了具有以下式（I）的1,3,4-噻二唑和1,3,4-氧二唑：其中，Y是S或O，R1是烷基，烯基，炔基，环烷基，杂环烷基，环烯基，芳基，杂芳基或多环基，可选择性地取代，R2是烷基，烯基，炔基，环烷基，杂环烷基，环烯基或芳基，可选择性地取代，R3是X2-R'3，其中X2是连接基，R'3是环烷基，杂环烷基，环烯基，芳基，杂芳基或多环基；可选择性地取代，或其药学上可接受的衍生物，其制备方法及其用于制造用于治疗需要通过PDE7抑制剂进行治疗的疾病的药物。
• USE OF PDE7 INHIBITORS FOR THE TREATMENT OF NEUROPATHIC PAIN
  申请人：Cox Peter

  公开号：US20090111837A1

  公开（公告）日：2009-04-30

  The present invention relates to the use of a phosphodiesterase 7 (PDE7) inhibitor in the manufacture of a medicament for the treatment of neuropathic pain and to a method of treating neuropathic pain using an inhibitor of PDE7.

  本发明涉及使用磷酸二酯酶7（PDE7）抑制剂制造治疗神经病理性疼痛药物以及使用PDE7抑制剂治疗神经病理性疼痛的方法。
• NEW THIADIAZOLES AND OXADIAZOLES AND THEIR USE AS PHOSPHODIESTERASE-7 INHIBITORS
  申请人：Warner-Lambert Company LLC

  公开号：EP1326853A1

  公开（公告）日：2003-07-16